From the February 2008 Idaho Observer:

According to Reuters and posted to Medscape.com, Rotarix, GlaxoSmithKline’s investigational rotavirus vaccine, is associated with increased pneumonia-related deaths and other adverse reactions, U.S. regulatory staff said. Analysis of 11 studies revealed a statistically-significant increase in deaths related to pneumonia in infants who had received Rotarix compared with a placebo in the largest of the 11 trials, according to documents posted on the FDA’s website Feb. 15, 2008.

That study, which enrolled about 63,000 children, also found an increase in convulsions in children given the vaccine. Another study found an increased rate of bronchitis compared with children receiving a placebo.

[Note: Although not FDA approved, hundreds of vaccines and drugs have been approved despite similar warning signs.]

Evidence of serious health consequences was recently confirmed in The Journal of Pediatrics in which CRP levels were measured after vaccination. CRP, short for C-reactive protein, is a blood marker indicating a heightened state of inflammation throughout the body.

The study involved infants in a neonatal intensive care unit who were given two or more vaccines on the same day. A separate group of infants were given one shot at a time, every three days. The vaccines administered were DTaP, Hib, polio [IPV], hepatitis B and Prevnar. The findings were disturbing:

• An abnormally elevated CRP occurred in 85 percent of infants who received simultaneous vaccines and nearly 70 percent of infants who received the shots one at a time.

• Gastro-esophageal reflux (GERD) and severe intraventricular hemorrhage (bleeding in the brain) also occurred in infants who received multiple vaccines at the same time.

• Cardio-respiratory events (stopped breathing) occurred in 16 percent of all infants within 48 hours after receiving the vaccines.

• Infants who received DTaP, Prevnar and Hib as single injections experienced the largest number of cardiorespiratory events overall. *

Other concerns about elevated CRP levels surfaced in 2004. In a study of 62 infants and small children who were part of the Diabetes Autoimmunity Study, those who had an elevated CRP level also had an increased risk of developing Type 1 (insulin-dependent) diabetes in childhood.**

In 2005 the global vaccine market was generating between $10 billion and $16 billion per year. According to the article "Booster Shot" (Forbes magazine, Nov. 12, 2007), "The global vaccine business is projected to grow 18 percent a year to $30 billion in 2011, well above the 4.4 percent annual growth expected by the drug industry overall. A new adult and adolescent vaccine market will make up a big portion of that growth."